Literature DB >> 2901378

Metformin enhances certain insulin actions in cultured rat hepatoma cells.

F Purrello1, D Gullo, M Buscema, V Pezzino, R Vigneri, I D Goldfine.   

Abstract

The effect of the oral antidiabetic agent metformin on insulin regulation of glycogen metabolism, tyrosine-aminotransferase activity, and [1-14C]aminoisobutyric acid uptake was studied in H4IIE cultured rat hepatoma cells. Metformin enhanced both basal (from 0.213 +/- 0.016 to 0.262 +/- 0.024 nmol/mg protein, p less than 0.01) and insulin stimulated [3H] glucose incorporation into glycogen in a time-dependent and dose-dependent manner. A small effect of metformin was seen at 1 mumol/l, and its greatest effects were obtained at 10 mumol/l. At the same concentrations, metformin did not influence basal tyrosine-aminotransferase activity but it potentiated insulin stimulated tyrosine-aminotransferase activity (+29.2 +/- 1.4%, p less than 0.01) and prevented the loss of tyrosine-aminotransferase responsiveness to insulin in H4IIE cells desensitised by a previous exposure to insulin. In contrast, metformin had no effect on basal or insulin-stimulated [1-14C]aminoisobutyric acid uptake. Over the concentrations of metformin that enhanced insulin action in H4IIE cells, the drug had no significant effect on insulin binding to its receptor. These studies suggest, therefore, that metformin may influence cellular metabolism by potentiating certain insulin actions through mechanisms that may be beyond insulin receptor binding.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901378     DOI: 10.1007/bf02341508

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  Direct effects of biguanides on glucose utilization in vitro.

Authors:  F Purrello; D Gullo; A Brunetti; M Buscema; S Italia; I D Goldfine; R Vigneri
Journal:  Metabolism       Date:  1987-08       Impact factor: 8.694

2.  Insulin receptor regulation and desensitization in rat hepatoma cells. Concomitant changes in receptor number and in binding affinity.

Authors:  M Crettaz; C R Kahn
Journal:  Diabetes       Date:  1984-05       Impact factor: 9.461

3.  Mechanism of action of metformin: insulin receptor and postreceptor effects in vitro and in vivo.

Authors:  I G Fantus; R Brosseau
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

Review 4.  Role of metformin in treatment of diabetes mellitus.

Authors:  R Vigneri; I D Goldfine
Journal:  Diabetes Care       Date:  1987 Jan-Feb       Impact factor: 19.112

5.  Effects of metformin on insulin receptor tyrosine kinase activity in rat adipocytes.

Authors:  D B Jacobs; G R Hayes; J A Truglia; D H Lockwood
Journal:  Diabetologia       Date:  1986-11       Impact factor: 10.122

Review 6.  Metformin: a review of its pharmacological properties and therapeutic use.

Authors:  L S Hermann
Journal:  Diabete Metab       Date:  1979-09

7.  Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats.

Authors:  A I Salhanick; P Konowitz; J M Amatruda
Journal:  Diabetes       Date:  1983-03       Impact factor: 9.461

8.  Disposition of metformin (N,N-dimethylbiguanide) in man.

Authors:  C R Sirtori; G Franceschini; M Galli-Kienle; G Cighetti; G Galli; A Bondioli; F Conti
Journal:  Clin Pharmacol Ther       Date:  1978-12       Impact factor: 6.875

9.  Extrapancreatic effects of sulfonylureas. Potentiation of insulin action through post-binding mechanisms.

Authors:  D H Lockwood; B L Maloff; S M Nowak; M L McCaleb
Journal:  Am J Med       Date:  1983-01-17       Impact factor: 4.965

10.  Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells.

Authors:  V Pezzino; V Trischitta; F Purrello; R Vigneri
Journal:  Diabetologia       Date:  1982-08       Impact factor: 10.122

View more
  1 in total

1.  Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin.

Authors:  F Anfosso; N Chomiki; M C Alessi; P Vague; I Juhan-Vague
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.